Apigenin suppresses insulin‐like growth factor I receptor signaling in human prostate cancer: An in vitro and in vivo study

Publisher： John Wiley & Sons Inc

E-ISSN： 1098-2744|48|3|243-252

ISSN： 0899-1987

Source： Molecular Carcinogenesis, Vol.48, Iss.3, 2009-03, pp. : 243-252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the insulin‐like growth factor‐1 receptor by picropodophyllin for lung cancer chemoprevention

By  

Molecular Carcinogenesis, Vol. 54, Iss. S1, 2015-06 ,pp. : E129-E137

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibition of lung adenocarcinoma cells by insulin‐like growth factor‐I receptor and Kirsten rat sarcoma mutations: A mutation analysis with antisense oligodeoxynucleotide

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 260-268

John Wiley & Sons Inc

Access to resources Recommend Favorite

Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3‐kinase‐mediated Akt signaling

By  

Molecular Carcinogenesis, Vol. 54, Iss. 9, 2015-09 ,pp. : 751-760

John Wiley & Sons Inc

Access to resources Recommend Favorite

Inhibitory effect of silibinin on ligand binding to erbB1 and associated mitogenic signaling, growth, and DNA synthesis in advanced human prostate carcinoma cells

By  

Molecular Carcinogenesis, Vol. 30, Iss. 4, 2001-01 ,pp. : 224-236

John Wiley & Sons Inc

Access to resources Recommend Favorite

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung

By  

Thoracic Cancer, Vol. 6, Iss. 3, 2015-05 ,pp. : 319-326

John Wiley & Sons Inc

Access to resources Recommend Favorite